Oral Abstracts


Information for Presenting Authors


Please find your presentation information below.

Thursday, March 23
Presentation Time Presenting Author Oral Number Abstract Title
10:00 - 10:10 AM Prachi Godiwala

O1

A DOUBLE-BLINDED PROSPECTIVE RANDOMIZED TRIAL COMPARING EUPLOIDY RATES AMONG EMBRYOS CREATED FROM SIBLING OOCYTES INJECTED WITH SPERM PROCESSED BY MICROFLUIDICS OR BY DENSITY GRADIENT CENTRIFUGATION.

10:15 - 10:25 AM
Fernanda Murillo

O2

CAUSAL INFERENCE INDICATES THAT POOR RESPONDERS GOING THROUGH A REPEAT CYCLE HAVE COMPARABLE OR BETTER OUTCOMES WITH ANTAGONIST PROTOCOL COMPARED TO FLARE

10:30 - 10:40 AM  Rachel Mandelbaum

O3

CLOMIPHENE CITRATE THROUGHOUT THE DURATION OF OVARIAN STIMULATION: AN APPROACH TO DECREASE COSTS, REDUCE INJECTION BURDEN, AND PREVENT PREMATURE OVULATION IN PATIENTS WITH DIMINISHED OVARIAN RESERVE
10:45 - 10:55 AM
Kate Devine

O4

DOES THE USE OF GNRH ANTAGONIST FOR OPTIMIZING TRANSFER DAY DECREASE SUCCESS IN MODIFIED NATURAL CYCLE FROZEN EMBRYO TRANSFERS?
11:00 - 11:10 AM  Joginder Bidhan

O5

EFFECT OF LENGTH OF TIME POST-MORTEM ON QUALITY AND FREEZING CAPACITY OF HUMAN TESTICULAR SPERMATOZOA

 Friday, March 24
Presentation Time Presenting Author Oral Number Abstract Title
 10:00 - 10:10 AM Matthew VerMilyea

O6

EMBRYO SEX IDENTIFICATION THROUGH A NON-INVASIVE ARTIFICIAL INTELLIGENCE (AI) ALGORITHM

 10:15 - 10:25 AM
Michael Neblett

O7

EVALUATION OF THE IN VIVO EFFICACY OF THE JAK INHIBITOR AZD1480 AGAINST UTERINE LEIOMYOMAS IN A PATIENT-DERIVED XENOGRAFT MOUSE MODEL
 10:30 - 10:40 AM 
Katherine Scott

O8

EXPLAINING FAILED EUPLOID BASTOCYST TRANSFER:  ENHANCED DETECTION OF SEGMENTAL ABNORMALITIES USING HIGH DENSITY TARGETED AMPLIFICATION
 10:45 - 10:55 AM Arian Khorshid

O9

MOSAIC EMBRYO TRANSFER VERSUS ADDITIONAL IVF WITH PGTA CYCLE: A DECISION MODEL COMPARING LIVE BIRTH RATE AND COST

 11:00 - 11:10 AM  Amanda Schwartz

O10

SHORT AND LONG-TERM TESTOSTERONE ADMINISTRATION IMPAIRS IN VITRO FERTILIZATION OUTCOMES WITH IMPROVEMENT FOLLOWING A WASHOUT PERIOD IN A MOUSE MODEL OF GENDER-AFFIRMING HORMONE CARE